Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Probiotics  COVID-19 treatment studies for Probiotics  C19 studies: Probiotics  Probiotics   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization time 14% Improvement Relative Risk Time to clinical improve.. 14% Time to viral- 17% Zhang et al. Probiotics for COVID-19 LATE TREATMENT Is late treatment with probiotics beneficial for COVID-19? Retrospective 300 patients in China Shorter hospitalization (p=0.009) and faster recovery (p=0.022) Zhang et al., Therapeutic Advances in Gastroente.., doi:10.1177/17562848211035670 Favors probiotics Favors control
Probiotics use is associated with improved clinical outcomes among hospitalized patients with COVID-19
Zhang et al., Therapeutic Advances in Gastroenterology, doi:10.1177/17562848211035670
Zhang et al., Probiotics use is associated with improved clinical outcomes among hospitalized patients with COVID-19, Therapeutic Advances in Gastroenterology, doi:10.1177/17562848211035670
Aug 2021   Source   PDF  
  All Studies   Meta
Retrospective 375 patients in China, 179 treated with probiotics (Bifidobacterium, Lactobacillus, and Enterococcus), showing improved clinical outcomes with treatment.
The immune effects of probiotics are strain-specific.
hospitalization time, 13.6% lower, relative time 0.86, p = 0.009, treatment 150, control 150, PSM.
time to clinical improvement, 14.3% lower, relative time 0.86, p = 0.02, treatment 150, control 150, PSM.
time to viral-, 16.7% lower, relative time 0.83, p < 0.001, treatment 150, control 150, PSM.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Zhang et al., 4 Aug 2021, retrospective, China, peer-reviewed, 14 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperProbioticsAll
Abstract: 1035670 research-article20212021 TAG0010.1177/17562848211035670Therapeutic Advances in GastroenterologyL Zhang, H Han Therapeutic Advances in Gastroenterology Original Research Probiotics use is associated with improved clinical outcomes among hospitalized patients with COVID-19 Ther Adv Gastroenterol 2021, Vol. 14: 1–9 DOI: 10.1177/ 17562848211035670 © The Author(s), 2021. Article reuse guidelines: Lina Zhang*, Huanqin Han*, Xuan Li*, Caozhen Chen*, Xiaobing Xie, Guomei Su, Shicai Ye, Cuili Wang, Qing He, Fang Wang, Fang Huang, Zhaoqin Wang, Jiayuan Wu and Tianwen Lai Abstract Background and aims: Currently, there are no definitive therapies for coronavirus disease 2019 (COVID-19). Gut microbial dysbiosis has been proved to be associated with COVID-19 severity and probiotics is an adjunctive therapy for COIVD-19. However, the potential benefit of probiotics in COVID-19 has not been studied. We aimed to assess the relationship of probiotics use with clinical outcomes in patients with COVID-19. Methods: We conducted a propensity-score matched retrospective cohort study of adult patients with COVID-19. Eligible patients received either probiotics plus standard care (probiotics group) or standard care alone (non-probiotics group). The primary outcome was the clinical improvement rate, which was compared among propensity-score matched groups and in the unmatched cohort. Secondary outcomes included the duration of viral shedding, fever, and hospital stay. Results: Among the propensity-score matched groups, probiotics use was related to clinical improvement rates (log-rank p = 0.028). This relationship was driven primarily by a shorter (days) time to clinical improvement [difference, −3 (−4 to −1), p = 0.022], reduction in duration of fever [−1.0 (−2.0 to 0.0), p = 0.025], viral shedding [−3 (−6 to −1), p < 0.001], and hospital stay [−3 (−5 to −1), p = 0.009]. Using the Cox model with time-varying exposure, use of probiotics remained independently related to better clinical improvement rate in the unmatched cohort. Conclusion: Our study suggested that probiotics use was related to improved clinical outcomes in patients with COVID-19. Further studies are required to validate the effect of probiotics in combating the COVID-19 pandemic. Keywords: clinical improvement, COVID-19, gut microbiota, probiotics Received: 11 April 2021; revised manuscript accepted: 29 June 2021.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop